Intranasal beclomethasone dipropionate in seasonal rhinitis in general practice.
Thirty-five patients with seasonal allergic rhinitis were treated in a double-blind comparative trial in and East London Group Practice with either beclomethasone dipropionate (50 micrograms in each nostril four times a day) or a placebo aerosol preparation identical in appearance. There was a statistically significant difference in favour of intranasal beclomethasone dipropionate (P less than 0-05).
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000031:analogs & derivatives*; D008875:Middle Aged; D010919:Placebos; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D000336:Aerosols; D006634:Histamine H1 Antagonists; D010919:Placebos; D001507:Beclomethasone; D008775:Methylprednisolone